---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-015796"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:43:04.963926+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tonix doses first patient in FOCUS study of intranasal oxytocin for AVP-D at MGH

## Summary
- First patient dosed in FOCUS study at Massachusetts General Hospital for arginine-vasopressin deficiency (AVP-D).
- Randomized, double-blind, placebo-controlled crossover pilot evaluating TNX-2900 (6 IU) and TNX-1900 (24 IU).
- Primary endpoints: markers of anxiety, depression, and socioemotional functioning; exploratory 2-week replacement on mental health.
- Study aims to generate preliminary data for future oxytocin replacement therapy in AVP-D.
- TNX-1900/TNX-2900 are intranasal Mg2+-potentiated oxytocin formulations in development for multiple conditions.

## SEC filing metadata
- accession: 0001999371-25-015796
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/0001999371-25-015796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125015796/tnxp_8k-102225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-015796
- JSON: https://secwatch.observer/filing/0001999371-25-015796.json
- Plain text: https://secwatch.observer/filing/0001999371-25-015796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.